We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Gene Panel Predicts Failure of Cutaneous Leishmaniasis Treatment

By LabMedica International staff writers
Posted on 03 Dec 2019
Print article
Image:  False color SEM (scanning electron microscope) micrograph of a Leishmania promastigote. The cell body is shown in orange and the flagellum is in red (Photo courtesy of Wikimedia Commons)
Image: False color SEM (scanning electron microscope) micrograph of a Leishmania promastigote. The cell body is shown in orange and the flagellum is in red (Photo courtesy of Wikimedia Commons)
Patients infected with the protozoan parasite Leishmania braziliensis develop chronic skin lesions that often fail to respond to treatment with anti-parasitic drugs.

Investigators at the University of Pennsylvania (Philadelphia, USA) sought to identify genes, which were differentially expressed among infected patients and which might be associated with the outcome of the disease. These genes could be useful as predictors of treatment failure and as targets for therapeutic drugs.

Towards this end, the investigators performed RNA sequencing (RNA-seq) of lesion biopsies taken from patients with cutaneous leishmaniasis at the initiation of treatment with pentavalent antimony and identified highly variable genes up-regulated relative to healthy skin. After RNA-seq of biopsies from two distinct patient cohorts and statistical filter strategies, they focused on a set of genes that were up-regulated in lesions from patients who did not respond to treatment, which included genes involved in cytolysis.

Given that cytolytic genes are induced early in the formation of the cutaneous leishmaniasis lesion, the investigators hypothesized that variations in the magnitude of expression of such genes might influence disease outcome and provide the potential markers to identify patients who may fail conventional therapy.

The results of the RNA-seq study revealed a prognostic signature comprising expression of three cytolytic genes. This gene panel combined with pathogen load predicted treatment response in two different patient cohorts and could potentially be used to triage patients who are unlikely to respond to conventional treatment as candidates for alternate therapies.

“The challenge of human studies is that there are so many confounding variables,” said contributing author Dr. Daniel P. Beiting, assistant professor of pathobiology at the University of Pennsylvania. “If you say, “I am going to compare people who have responded to those who did not respond,” it sometimes does not work because in those two groups there are a lot of other variables at play - sex, age, other co-morbidities. So what we did instead was say, “If we believe these patients are variable in the way they respond to treatment, why not look at what genes are variable?”

The study was published in the November 20, 2019, online edition of the journal Science Translational Medicine.

Related Links:
University of Pennsylvania

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.